



All

Images

Videos

翻译成中文

关闭取词

409 Results

Any time ▾

[Challenges Persist With CAR T-Cell Therapy in Pancreatic ...](#)



Targeted Oncology

16 hours ago · At Penn, Beatty's laboratory developed a CAR specific for mesothelin, a protein that is overexpressed by **pancreatic ductal adenocarcinoma** cells. In vitro, CAR T cells engineered to express mesothelin "will react and kill **tumor** cells that are ...

[The Oncolytic Virotherapy Era in Cancer Management ...](#)

<https://www.frontiersin.org/articles/10.3389/fonc.2017.00093> ▾

In the respective preclinical models, efforts have been made to unravel the mechanisms and improve the efficacy of H-1PV **treatment**. **Pancreatic Cancer**. **Pancreatic ductal adenocarcinoma** (PDAC) is a highly aggressive **tumor**, often unresectable at the time ...

[Pomalidomide Alters Pancreatic Macrophage Populations to ...](#)

<cancerres.aacrjournals.org/content/79/7/1535> ▾

The **microenvironment** surrounding **pancreatic** lesions and **cancer** cells is mainly composed of fibroblasts and immune cells, and is an important factor affecting **tumor** development and growth, **tumor** cell dissemination, and **treatment** efficacy.

[Inhibition of geranylgeranyl diphosphate synthase is a ...](#)

www.nature.com › [oncogene](#)

7 days ago · **Pancreatic ductal adenocarcinoma** (PDAC) is characterized by abnormal mucin production and these mucins play important roles in **tumor** ...

[TAMing pancreatic cancer: combat with a double edged ...](#)

<https://molecular-cancer.biomedcentral.com/articles/10.1186/s12943...>

4 days ago · **Pancreatic Ductal Adenocarcinoma** (PDAC) is the most common **cancer**, constituting nearly 90% of all **pancreatic** cancers. Surgical resection continues to be the only definitive **treatment** for PDAC, yet, the fraction of patients who have **tumors** that are amenable to surgical resection is only approximately 10–20% [7].

Name of Journal: *World Journal of Gastrointestinal Oncology*

Manuscript NO: 47888

Manuscript Type: MINIREVIEWS

Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy

Sarantis P *et al.* Immunotherapy and pancreatic cancer

Panagiotis Sarantis, Evangelos Koustas, Adriana Papadimitropoulou, Athanasios G Papavassiliou, Michalis V Karamouzis

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal diseases,

Match Overview

Match #	Source	Words	Similarity
1	Internet crawled on 22-Jun-2017 www.mskcc.org	28	1%
2	Internet crawled on 10-Jan-2018 www.mdpi.com	27	1%
3	Crossref Gunturu, K. S., G. R. Rossi, and S. M. Wasif. "Immunotherapy updates in pancreatic cancer: are we there yet?", <i>Th</i>	20	1%
4	Internet crawled on 10-Jan-2018 pancreapedia.org	20	1%
5	Internet crawled on 14-Jun-2018 science.sciencemag.org	19	1%
6	Internet crawled on 29-Mar-2015 www.ncbi.nlm.nih.gov	18	1%
7	Crossref J. M. Kim, D. S. Chen. "Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure)", <i>Annals of</i>	17	1%
8	Internet crawled on 18-Sep-2019 www.frontiersin.org	15	1%
9	Internet crawled on 08-Apr-2018 cancerbiomedcentral.com	15	1%
10	Crossref Elodie Roger, Sylvie Martel, Adrien Bertrand-Chapel, Arnould Depollier et al. "Schwann cells support oncogenic ...	13	<1%
11	Internet crawled on 17-Jul-2018 clincancerres.aacrjournals.org	13	<1%



All

Images

Videos

关闭取词

27,000 Results

Any time ▾

Immunotherapy for pancreatic ductal adenocarcinoma: an ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4560736>

Mar 18, 2015 · Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related death and current therapeutic strategies are often unsatisfactory. Identification and development of more efficacious therapies is urgently needed.

Cited by: 14

Author: Alessandro Paniccia, Justin Merkow, Bari...

Publish Year: 2015

Pancreatic cancer microenvironment, to target or not to ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4734844>

Jan 08, 2016 · The specific example of pancreatic ductal adenocarcinoma (PDAC) illustrates both the shortcomings of conventional therapies and the importance of the PDAC microenvironment in clinical outcomes. PDAC is a highly lethal malignancy with ~80% of patients presenting with locally advanced disease.

Cited by: 16

Author: Ryan M Carr, Martin E Fernandez-Zapico

Publish Year: 2016

Frontiers | Pancreatic Ductal Adenocarcinoma: A Strong ...

<https://www.frontiersin.org/articles/10.3389/fimmu.2018.01044> ▾

May 14, 2018 · Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and lethal cancers with very few available treatments. For many decades, gemcitabine was the only treatment for patients with PDAC.

Cited by: 11

Author: Etienne Dominique Foucher, Clément Ghi...

Publish Year: 2018

Targeting the tumor microenvironment for pancreatic ductal ...

[cco.amegroups.com/article/view/25114/23704](https://www.frontiersin.org/articles/10.3389/fimmu.2019.01044) ▾

Pancreatic ductal adenocarcinoma (PDAC) is one of the most dangerous cancers, and the overall 5-year survival rate is only 8%. The microenvironment of PDAC, which promotes tumorigenesis, disease development and metastasis, consists of fibroblasts, immune cells, pancreatic stellate cells (PaSCs), adipocytes and extracellular matrix (ECM).

Author: Yi-Fan Zhang, Shu-Heng Jiang, Li-Pen...

Publish Year: 2019



All

Images

Videos

关闭取词

26,900 Results

Any time ▾

Pancreatic cancer microenvironment, to target or not to ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4734844>

Jan 08, 2016 · The specific example of **pancreatic ductal adenocarcinoma (PDAC)** illustrates both the shortcomings of conventional **therapies** and the importance of the **PDAC microenvironment** in clinical outcomes. PDAC is a highly **lethal malignancy** with ~80% of patients presenting with locally advanced **disease**.

Cited by: 16

Author: Ryan M Carr, Martin E Fernandez-Zapico

Publish Year: 2016

Immunotherapy for pancreatic ductal adenocarcinoma: an ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4560736>

Mar 18, 2015 · The **pancreatic cancer microenvironment**. **Pancreatic ductal adenocarcinoma (PDAC)** presents several challenges that set it apart from those more immunogenic **tumors**, such as melanoma and renal cell **cancer** (17,18).A dysregulation of the immune system is one of the facilitating factors for PDAC development, thus legitimizing the role of the immune network in PDAC (19-22).

Cited by: 14

Author: Alessandro Paniccia, Justin Merkow, Bari...

Publish Year: 2015

Pancreatic cancer microenvironment: a current dilemma

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6333596>

Jan 15, 2019 · To date, the **mainstay treatment** of **pancreatic cancer** is a combination of **cytotoxic agents** in **adjuvant** and **metastatic settings** [5, 6]. Despite efforts in the past decades, targeted **therapy** approaches have not yielded substantial improvement in clinical outcomes essentially due to complex signaling pathways .

Cited by: 2

Author: Burak Uzunparmak, Ibrahim Halil Sahin

Publish Year: 2019

Frontiers | Pancreatic Ductal Adenocarcinoma: A Strong ...

<https://www.frontiersin.org/articles/10.3389/fimmu.2018.01044> ▾

May 14, 2018 · **Pancreatic ductal adenocarcinoma (PDAC)** is one of the most aggressive and **lethal cancers** with very few available **treatments**. For many decades, **gemcitabine** was the only **treatment** for patients with PDAC.

Cited by: 11

Author: Etienne Dominique Foucher, Clément Ghi...

Publish Year: 2018